FDA NDC

APRISO

This name is from the loaded FDA file.

Source: FDA NDC Directory, live from openFDA. Publisher page

NDC
65649-103
Proprietary name
APRISO
Nonproprietary name
mesalamine
Labeler
Salix Pharmaceuticals, Inc.
Dosage form
CAPSULE, EXTENDED RELEASE
Strength
375 mg/1

Run it in Rivvi

Which 2027 plans near you dropped or restricted mesalamine?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan, from the CMS Part D files.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Try it on your own data today.

Free to start. Most teams are using it the same day.